China moves to ban biotech platform ownership transfers while preserving licensing routes

China's Ministries of Commerce and Science and Technology proposed export controls banning overseas ownership transfers of proprietary cell and gene therapy and siRNA biotech platforms, while allowing licensing and specific drug-development transactions. An interim pre-export registration requirement is already in effect, covering all relevant technology export transactions.

This Wire brief sits within Fusion42's coverage of Biotech.